Home
overview

Allergies are currently skyrocketing. In this current day and age it is reckoned that one in five people have an allergy.


Previously there had been very little knowledge of what caused allergies and how to combat them. The aversion strategy had been the main form of attack against the prevalence of an adverse immune attack. However, this has seemingly not been the best approach.
Immunotherapy techniques have been developed to wean the body to accepting immunogenic samples by queuing the response to them and sensitising the body to the exposure of allergens. The field is very much in its infancy with a range of exciting discoveries giving hope to people suffering from allergies.


However, there is a great lack of understanding on matters of how to administer therapy in an effective manner and how to increase patient compliance.  

The second annual Allergies conference takes place on the 8th-9th of July 2015 at the Marriott Regents Park, London and will introduce the audience to a range of new developments in the field and allow for an understanding of where the field of allergy therapeutics is going.
The agenda focuses on a range of hot topics:


• Development of novel vaccines and adjuvants for immunotherapy
Regulation and clinical trials for paediatric immunotherapy to allow for a strong understanding of the current requirements and obligations in the development of immunotherapy products.
• Increasing patient compliance and increasing the quality of life for the patients that are being treated on a day to day basis with therapeutics.
Personalised medicines for the treatment of specific phenotypes rather than taking the one fits all strategy.
New pathways will be discussed and elaborated to allow for new targeting strategies to be developed.
 

Join us and hear expert opinions on these and many more topics in the field of Allergy therapeutics.
 

• Discussing recent breakthroughs in the field of allergy therapeutics
• Ultra-Fast Desensitisation
• Understanding why it is important to make vaccines immunogenic for the correct responses
Standardisation and Regulation in immunotherapy products: What’s new?
• Paediatric randomised clinical trials for allergy therapeutics
• Development of Allergenoid therapeutics.
 

This event is aimed at Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in:
Immunotherapy Drug Discovery
Allergy Medicine
Allergy Pharmacology
Immunotherapy
Research Immunology
Pharmacology
Immunotherapy Licensing
Inflammation and Autoimmunity
Immunology
Allergy Cell Biology
Allergy Therapeutics
Allergy Devices
Medical Devices
Inflammation Discovery
Allergy Medicine Regulation

Addenbrookes Hospital; allergy therapeutics; Allergy Therapeutics Ltd; Anergis; Biomay AG; Circassia; Department of Pathophysiology and Allergy Research; GlaxoSmithKline; Imperial College Administration; Imperial College London; Johnson & Johnson Innovation ; JOHNSON + JOHNSON; Laboratorios Leti; MedImmune; National Heart and Lung Institute; Nestle Research Center; NJ Center for Oral Surgery; Novartis; Nutricia Research; Nuvo Research GmbH; Nuvo Research Inc.; Quintiles; Root Lines Technology ; Royal Free Hospital; Royal National Ear Nose & Throat Hosp; Swecure; TNO; University Of Vienna;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Adam Chaker

Adam Chaker, Head of Research Group, The Center of Allergy and Environment

9:10 Challenges in the development of allergen immunotherapies

Rod Hafner

Rod Hafner, Senior Vice President Research and Development, Circassia Ltd

• An introduction into the current situation in allergen immunotherapies
• Identification of key challenges and opportunities in the field
• Synthetic Peptide Immuno-Regulatory Epitopes: a new class of compounds
 

9:50 Specific Immunotherapy under the umbrella of anti IL-4: a new perspective for patients?

Adam Chaker

Adam Chaker, Head of Research Group, The Center of Allergy and Environment

• Targeting allergen specific responses and Treg induction
• Sustained reduction of allergen specific responses in vivo
• Clinical Phase IIa study with rational biological vaccine design

10:30 Morning Coffee

11:00 Oral Mucosal Immunotherapy (OMIT): A new approach to delivering allergen-specific immunotherapy

Kate  Rochlin

Kate Rochlin, CSO, Immunovent

• Allergen extracts stabilized in a fully-functional toothpaste, simultaneously delivering dental care and immunotherapy
• Support for long-term, daily adherence for optimal outcomes
• Potential optimization of dosing efficiency; patient convenience

11:40 Epicutaneous immunotherapy, a new treatment in life threatening food allergies

Lucie Mondoulet

Lucie Mondoulet, Director of Research Department, DBV Technologies

• mechanisms of action and pre-clinical data
• Clinical development and Phase IIb results
• Future developments in prevention and impact on allergic march

12:20 Networking Lunch

13:30 Formulation and delivery of state of the art allergy therapeutics

Tim Higenbottam

Tim Higenbottam, Research & Development Director, Allergy Therapeutics Ltd

• Formulation of new adjuvants
• Development of novel allergenoid technologies
• Understanding the potential for slow-release depot formulations for allergy vaccines, increasing the safety profile and enhancing the efficacy-associated immunological changes

 

 

14:10 Paediatric trials with specific immunotherapy

Angelika 	 Sager

Angelika Sager , Medical director , Leti Laboratories

• Ethical issues with performing immunotherapy trials
• Ensuring optimal controls in paediatric trials
• Case studies in paediatric immunotherapy trials

14:50 Afternoon Tea

15:20 Confirmatory trials – is a field study still the gold standard?

Diderik Boot

Diderik Boot, Medical Director, HAL-Allergy

• Recent advances in provocation models
• Standardisation of outcome measures during field studies
• Understanding the field of allergies.
• Phase III trials and the role of environmental exposure

16:00 Increasing probability of success in allergy clinical trials

Juan Gispert

Juan Gispert, Senior medical director. European Head Allergy, Respiratory, Infectious Diseases and Vaccines, Quintiles

• Recruitment of patients
• Compliance in long term trials
• Clinical trials in paediatric population
 

16:40 Mechanisms and biomarkers for monitoring allergen-specific immunotherapy

Mohamed  Shamji

Mohamed Shamji, Group leader/Senior Research Fellow, Imperial College London Faculty of Medicine

  • Mechanisms of allergen immunotherapy
  • Mechanisms of tolerance induction following allergen immunotherapy
  • Biomarkers for monitoring clinical efficacy of immunotherapy
  • 17:20 Chairman's Closing Remarks and Close of Day Two

    Adam Chaker

    Adam Chaker, Head of Research Group, The Center of Allergy and Environment

    8:30 Registration & Coffee

    9:00 Morning Chairman's Opening Remarks

    Ian Strickland

    Ian Strickland, Research Scientist, MedImmune

    9:10 Advances in the field of Atopic Dermatitis

    Ian Strickland

    Ian Strickland, Research Scientist, MedImmune

    • New biology describing distinct patient subpopulations
    • Targeting the Th2 axis in atopic dermatitis with high potency therapeutic antibodies
    • Bacterial exacerbation of disease, current and future treatments

    9:50 Sublingual Immunotherapy vs Sub cutaneous immunotherapy

    Guy  Scadding

    Guy Scadding, Specialist registrar, Royal Brompton Hospital

    • Reviewing the current science and history of SLIT
    • Discussing the indications, efficacy, safety, duration and mechanisms of sublingual immunotherapy
    • Comparison with subcutaneous immunotherapy

     

    10:30 Morning Coffee

    11:00 Safety data management in the field of allergy therapeutics

    Inmaculada Cerecedo

    Inmaculada Cerecedo, Medical Advisor, Laboratorios Leti

    • Understanding requirements
    • Safety and efficacy of subcutaneous immunotherapy
    • State of the art of allergy pharmacovigilance

    11:40 LAMB-Dx – A Novel Approach To Food And Respiratory Allergy Diagnosis Through The Detection Of Local IgE

    Kate  Rochlin

    Kate Rochlin, CSO, Immunovent

    • Local Antibody Mucosal Brush Test Accurately Identifies Specific IgE
    • Evidence Shows That LAMB-Dx Can Be Used To Detect Allergic Sensitivities In Non-Allergic Rhinitis Patients
    • Evidence Indicates The Clinical Utility Of LAMB-Dx As A Needle Free Clinical Diagnostic
     

    12:20 Networking Lunch

    13:20 Afternoon Chairman's Opening Remarks

    Tracy  Hussell

    Tracy Hussell, Centre Director MCCIR, Manchester University

    13:30 Novel anti-inflammatory agents in immune-mediated ocular diseases

    Virginia Calder

    Virginia Calder, Senior Lecturer, UCL

    • Discussing several in vitro models of autoimmune and allergic eye diseases
    • Unravelling the molecular mechanisms involved in subtypes of ocular disease.
    • Cytokine profiles as an explanation for the varied responses of individuals to therapies
     

    14:10 Testing new uncharted pathways involved in Asthma

    Tracy  Hussell

    Tracy Hussell, Centre Director MCCIR, Manchester University

    • Test the hypothesis that the remodelled epithelium over-regulates airway macrophages in patients with COPD or Asthma
    • Therapeutic manipulation of such regulatory pathways would re-set the inflammatory tone in the lung and prevent exacerbation of chronic disease
    • Providing opportunities to slow or stop disease progression

    14:50 Afternoon Tea

    15:20 Involvement in Clinical Trials, the Patients Perspective

    Lynne Regent

    Lynne Regent, CEO, Anaphylaxis Campaign

    • The Role of the patient organisation
    • The view of the Patient
    • Improving the experience

     

    16:00 Environmental Exposure Chambers for Use in Pivotal Allergy Trials

    Anne Marie  Salapatek

    Anne Marie Salapatek, President & Chief Scientific Officer, Inflamax Research, Inc.

    • EECs provide an ability to test allergy therapeutics accurately and precisely and to provide results that are representative of real world efficacies
    • EEC models for range finding or proof of concept studies towards the development of immunotherapies
    • The ideal multicenter mobile EEC/field hybrid approach for pivotal phase III allergy trials
     

    16:40 Chairman’s Closing Remarks and Close of Day Two

    Tracy  Hussell

    Tracy Hussell, Centre Director MCCIR, Manchester University

    +

    FEATURED SPEAKERS

    Lynne Regent

    Lynne Regent

    CEO, Anaphylaxis Campaign
    Rod Hafner

    Rod Hafner

    Senior Vice President Research and Development, Circassia Ltd
    Tim Higenbottam

    Tim Higenbottam

    Research & Development Director, Allergy Therapeutics Ltd
    Tracy  Hussell

    Tracy Hussell

    Centre Director MCCIR, Manchester University
    Virginia Calder

    Virginia Calder

    Senior Lecturer, UCL

    Adam Chaker

    Head of Research Group, The Center of Allergy and Environment
    Adam Chaker

    Angelika Sager

    Medical Director , Leti Laboratories
    Angelika Sager

    Anne Marie Salapatek

    President & Chief Scientific Officer, Inflamax Research, Inc.
    Anne Marie  Salapatek

    Diderik Boot

    Medical Director, HAL-Allergy
    Diderik Boot

    Guy Scadding

    Specialist registrar, Royal Brompton Hospital
    Guy  Scadding

    Ian Strickland

    Research Scientist, MedImmune
    Ian Strickland

    Inmaculada Cerecedo

    Medical Advisor, Laboratorios Leti
    Inmaculada Cerecedo

    Juan Gispert

    Senior medical director. European Head Allergy, Respiratory, Infectious Diseases and Vaccines, Quintiles
    Juan Gispert

    Kate Rochlin

    CSO, Immunovent
    Kate  Rochlin

    Lucie Mondoulet

    Director of Research Department, DBV Technologies
    Lucie Mondoulet

    Lynne Regent

    Chief Executive Officer, anaphylaxis campagne
    Lynne Regent

    Lynne Regent

    CEO, Anaphylaxis Campaign
    Lynne Regent

    Mohamed Shamji

    Group leader/Senior Research Fellow, Imperial College London Faculty of Medicine
    Mohamed  Shamji

    Rod Hafner

    Senior Vice President Research and Development, Circassia Ltd
    Rod Hafner

    Tim Higenbottam

    Research & Development Director, Allergy Therapeutics Ltd
    Tim Higenbottam

    Tracy Hussell

    Centre Director MCCIR, Manchester University
    Tracy  Hussell

    Virginia Calder

    Senior Lecturer, UCL
    Virginia Calder

    Sponsors and Exhibitors

    Supporting Media Partners

    Supporters

    Workshops

    Improving probability of success in allergy clinical trials
    Workshop

    Improving probability of success in allergy clinical trials

    Marriott Regents Park
    7th July 2015
    London, United Kingdom

    Tear Biomarkers For Ocular Allergy
    Workshop

    Tear Biomarkers For Ocular Allergy

    Marriott Regents Park
    7th July 2015
    London, United Kingdom

    Is your name on the list for Allergies 2015?

    Download

    Sponsors and Exhibitors


    DBV Technologies

    Sponsors and Exhibitors
    http://www.dbv-technologies.com/en

    DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT®, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin®. We are advancing this unique technology to treat patients, including infants and children, suffering from severe food allergies (Peanut, Milk, Egg).


    Inflamax Research

    Sponsors and Exhibitors
    http://www.inflamaxresearch.com/

    Inflamax Research is a full-service, global CRO that specializes in allergy, asthma, ocular and dermatology research with extensive experience in the design and conduct of Phase I-IV clinical trials. Inflamax offers Natural Environmental Exposure Chamber (EEC) models and has a unique, patented mobile EEC (mEEC™) model which can be located anywhere worldwide for use in multi-center trials. We also offer our sponsors two fully-equipped, 100 bed Phase I units, located in Toronto, CANADA and Neptune, NEW JERSEY.

    Media Partners


    http://www.fiercebiotech.com" target="_blank"> sponsor image

    FierceBiotech

    Supporting Media Partners
    http://www.fiercebiotech.com" target="_blank" class="link" align="right"> http://www.fiercebiotech.com

    FierceBiotech is the biotech industry's daily monitor. Biotech executives rely on FierceBiotech to stay up to speed on biotech corporations, FDA approvals & regulations, industry mergers & acquisitions, clinical trials, and more. Beyond the news of the day, our editors produce in-depth features on industry leaders and up-and-comers, the regulatory environment, and market trends. In addition to our comprehensive website and free email newsletter, you have the opportunity to attend our webinars, peruse our whitepaper library and benefit from our eBooks. Advance your career through our exclusive networking parties and life sciences job board.

    Media Partners


    International Journal of Computational Biology and Drug Design

    Supporters
    http://www.inderscience.com/ijcbdd

    IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    International Journal of Bioinformatics Research and Applications

    Supporters
    http://www.inderscience.com/ijbra

    Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.


    International Journal of Medical Engineering and Informatics

    Supporters
    http://www.inderscience.com/ijmei

    IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Int. J. of Immunological Studies

    Supporters
    http://www.inderscience.com/ijis

    IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.


    Medical News Today

    Supporters
    http://www.medicalnewstoday.com

    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


    International Journal of Biotechnology

    Supporters
    http://www.inderscience.com/ijbt

    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.